• Publications
  • Influence
Multiphase composites with extremal bulk modulus
Abstract This paper is devoted to the analytical and numerical study of isotropic elastic composites made of three or more isotropic phases. The ranges of their effective bulk and shear moduli areExpand
  • 248
  • 16
Variational principles for complex conductivity, viscoelasticity, and similar problems in media with complex moduli
Linear processes in media with dissipation arising in conductivity, optics, viscoelasticity, etc. are considered. Time‐periodic fields in such media are described by linear differential equations forExpand
  • 87
  • 14
Approximations of the target-mediated drug disposition model and identifiability of model parameters
TLDR
This paper introduces quasi-steady-state (QSS) and Michaelis-Menten (MM) approximations of the TMDD model and proposes an algorithm for establishing identifiability of these models, and tests this algorithm on simulated datasets. Expand
  • 190
  • 9
  • PDF
Connection between the conductivity and bulk modulus of isotropic composite materials
Rigorous cross-property bounds that connect the effective electrical conductivity σ* and the effective bulk modulus K* of any isotropic two-phase composite are derived when the volume fractions ofExpand
  • 80
  • 7
Coupled estimates for the bulk and shear moduli of a two-dimensional isotropic elastic composite
Abstract We improve the classical Hashin-Shtrikman and Walpole estimates of the effective properties for an isotropic mixture assembled from two isotropic elastic materials. The planar elasticityExpand
  • 75
  • 7
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics
Models for drugs exhibiting target-mediated drug disposition (TMDD) describe biological processes in which drug-target binding significantly influences both pharmacodynamics (PD) and pharmacokineticsExpand
  • 79
  • 4
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to rituximab in clinical trials for non‐Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, theExpand
  • 56
  • 4
Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours
Background and ObjectiveDenosumab (XGEVA®; AMG 162) is a fully human IgG2 monoclonal antibody, which binds to the receptor activator of nuclear factor K-B ligand (RANKL) and prevents terminalExpand
  • 55
  • 4
Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor
ABSTRACTPurposeFor AMG 317, a fully human monoclonal antibody to interleukin receptor IL-4Rα, we developed a population pharmacokinetic (PK) model by fitting data from four early phase clinicalExpand
  • 42
  • 4